+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

LAMEA Contrast Media Market, by Product Type, by Application, by Modality, by Country, Industry Analysis and Forecast, 2019 - 2025

  • ID: 5006198
  • Report
  • February 2020
  • Region: Africa, Middle East
  • 96 Pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Bayer AG
  • Bracco S.p.A.
  • Lantheus Holdings, Inc.
  • The Guerbet Group
The Latin America, Middle East and Africa Contrast Media Market is expected to witness market growth of 4.55% CAGR during the forecast period (2019-2025).

Development of the contrast media market in Middle Eastern and Latin American countries is influenced by the growing inclination towards picture guided diagnostics and strategies. Another key trend noticed is the rising mortality of interminable ailments like gastrointestinal disarranges and cardiovascular diseases. That being said, there are various adverse effects of contrast media on the body and also, they come with infeasible costs. These factors impeded market growth in this region to some extent.

The contrast media of gadolinium consists of complex molecules, arrangements of atoms bound together by chemical bonds. A gadolinium ion and a carrier molecule (a chelating agent) form the chemical bonds. A chelating agent prevents gadolinium from being toxic while preserving its contrasting properties. Different contrast medium brands of gadolinium use specific chelating molecules. The contrast medium is injected intravenously (into a vein) as part of an MRI scan and removed from the body through the kidneys.

Ultrasound segment growth can be largely attributed to several benefits offered by ultrasound contrast agents over other contrast agents and the increasing number of approvals for ultrasound contrast agents in the US, Europe, and Japan. Cardiovascular MRI is primarily being used to test cardiac masses, ischemic heart disease, complex congenital heart disease, and vascular anatomy all through the body. Several diversified contrast media can be used to improve the sensitivity and specificity of detecting and assessing various pathologies, and knowledge of these agents' different mechanisms of action, distribution and protection profiles is needed for safe and effective imaging.

Based on Product Type, the market is segmented into Iodinated, Barium-based, Gadolinium-based and Microbubble. Based on Application, the market is segmented into Neurological disorders, Cancer, Cardiovascular disorders, Gastrointestinal disorders, Nephrological disorders, Musculoskeletal disorders and Other Applications. Based on Modality, the market is segmented into X-ray/CT, MRI and Ultrasound. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, General Electric (GE) Co. (GE Healthcare), The Guerbet Group, Lantheus Holdings, Inc., Bracco S.p.A., Trivitron Healthcare Pvt. Ltd., Nano Therapeutics Pvt. Ltd., Magnus Health, LLC (Veracross LLC), Imax Diagnostic Imaging Limited, and Daiichi Sankyo Company, Limited.

Scope of the Study

Market Segmentation:

By Product Type
  • Iodinated
  • Barium-based
  • Gadolinium-based
  • Microbubble

By Application
  • Neurological disorders
  • Cancer
  • Cardiovascular disorders
  • Gastrointestinal disorders
  • Nephrological disorders
  • Musculoskeletal disorders
  • Other Applications

By Modality
  • X-ray/CT
  • MRI
  • Ultrasound

By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled
  • Bayer AG
  • General Electric (GE) Co. (GE Healthcare)
  • The Guerbet Group
  • Lantheus Holdings, Inc.
  • Bracco S.p.A.
  • Trivitron Healthcare Pvt. Ltd.
  • Nano Therapeutics Pvt. Ltd.
  • Magnus Health, LLC (Veracross LLC)
  • Imax Diagnostic Imaging Limited
  • Daiichi Sankyo Company, Limited

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Bracco S.p.A.
  • Lantheus Holdings, Inc.
  • The Guerbet Group

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Latin America, Middle East and Africa (LAMEA) Contrast Media Market, by Product Type
1.4.2 Latin America, Middle East and Africa (LAMEA) Contrast Media Market, by Application
1.4.3 Latin America, Middle East and Africa (LAMEA) Contrast Media Market, by Modality
1.4.4 Latin America, Middle East and Africa (LAMEA) Contrast Media Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Executive Summary
2.1.3 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Mergers & Acquisitions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2015-2019)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions : Sep, 2019-Mar, 2015) Leading Players
Chapter 4. LAMEA Contrast Media Market by Product Type
4.1 LAMEA Iodinated Market by Country
4.2 LAMEA Barium-based Market by Country
4.3 LAMEA Gadolinium-based Market by Country
4.4 LAMEA Microbubble Market by Country
Chapter 5. LAMEA Contrast Media Market by Application
5.1 LAMEA Neurological disorders Market by Country
5.2 LAMEA Cancer Market by Country
5.3 LAMEA Cardiovascular disorders Market by Country
5.4 LAMEA Gastrointestinal disorders Market by Country
5.5 LAMEA Nephrological disorders Market by Country
5.6 LAMEA Musculoskeletal disorders Market by Country
5.7 LAMEA Other Applications Market by Country
Chapter 6. LAMEA Contrast Media Market by Modality
6.1 LAMEA X-ray/CT Market by Country
6.2 LAMEA MRI Market by Country
6.3 LAMEA Ultrasound Market by Country
Chapter 7. LAMEA Contrast Media Market by Country
7.1 Brazil Contrast Media Market
7.1.1 Brazil Contrast Media Market by Product Type
7.1.2 Brazil Contrast Media Market by Application
7.1.3 Brazil Contrast Media Market by Modality
7.2 Argentina Contrast Media Market
7.2.1 Argentina Contrast Media Market by Product Type
7.2.2 Argentina Contrast Media Market by Application
7.2.3 Argentina Contrast Media Market by Modality
7.3 UAE Contrast Media Market
7.3.1 UAE Contrast Media Market by Product Type
7.3.2 UAE Contrast Media Market by Application
7.3.3 UAE Contrast Media Market by Modality
7.4 Saudi Arabia Contrast Media Market
7.4.1 Saudi Arabia Contrast Media Market by Product Type
7.4.2 Saudi Arabia Contrast Media Market by Application
7.4.3 Saudi Arabia Contrast Media Market by Modality
7.5 South Africa Contrast Media Market
7.5.1 South Africa Contrast Media Market by Product Type
7.5.2 South Africa Contrast Media Market by Application
7.5.3 South Africa Contrast Media Market by Modality
7.6 Nigeria Contrast Media Market
7.6.1 Nigeria Contrast Media Market by Product Type
7.6.2 Nigeria Contrast Media Market by Application
7.6.3 Nigeria Contrast Media Market by Modality
7.7 Rest of LAMEA Contrast Media Market
7.7.1 Rest of LAMEA Contrast Media Market by Product Type
7.7.2 Rest of LAMEA Contrast Media Market by Application
7.7.3 Rest of LAMEA Contrast Media Market by Modality
Chapter 8. Company Profiles
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.1.5.2 Approvals:
8.2 General Electric (GE) Co. (GE Healthcare)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Product Launches and Product Expansions:
8.2.6 SWOT Analysis
8.3 The Guerbet Group
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.3.5.3 Product Launches and Product Expansions:
8.4 Lantheus Holdings, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.5 Bracco S.p.A.
8.5.1 Company Overview
8.5.2 Regional Analysis
8.5.3 Recent strategies and developments:
8.5.3.1 Product Launches and Product Expansions:
8.5.3.2 Acquisition and Mergers:
8.5.3.3 Approvals:
8.6 Trivitron Healthcare Pvt. Ltd.
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Partnerships, Collaborations, and Agreements:
8.7 Nano Therapeutics Pvt. Ltd.
8.7.1 Company Overview
8.8 Magnus Health, LLC (Veracross LLC)
8.8.1 Company Overview
8.9 Imax Diagnostic Imaging Limited
8.9.1 Company Overview
8.1 Daiichi Sankyo Company, Limited
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
Note: Product cover images may vary from those shown
  • Bayer AG
  • General Electric (GE) Co. (GE Healthcare)
  • The Guerbet Group
  • Lantheus Holdings, Inc.
  • Bracco S.p.A.
  • Trivitron Healthcare Pvt. Ltd.
  • Nano Therapeutics Pvt. Ltd.
  • Magnus Health, LLC (Veracross LLC)
  • Imax Diagnostic Imaging Limited
  • Daiichi Sankyo Company, Limited
Note: Product cover images may vary from those shown

Loading
LOADING...